Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Addenbrookes Hospital, Cambridge, United Kingdom



Survival: 6.5 months
   
Toxicity Grade: 3
   
Treatments: Biologic therapy
   
Drugs:
Country: United Kingdom
   
City/State/Province: Cambridge
   
Hospital: Addenbrookes Hospital
   
Journal: Link
   
Date: 10/2010

Description:
Patients:
This study involved 34 patients with metastatic melanoma. The median patient age was 62 years and 62% were male.

Treatment:
Patients were given the biologic agent vatalanib, a tyrosine kinase inhibitor. This drug functions as an anti-angiogenesis agent and inhibits blood vessel growth in tumors.

Toxicities:
The highest toxicity grade reported was 3, mostly consisting of hypertension and elevated liver enzymes. Other reported toxicities included proteinuria, dizziness, fatigue, and nausea.

Results:
The median overall survival reported in this study was 6.5 months. Median progression-free survival was 1.8 months.

Support:
This study was partially supported by Bayer Schering Pharma, makers of vatalanib.

Correspondence: Dr. Pippa G. Corrie; email: pippa.corrie@addenbrookes.nhs.uk

E-mail to a Friend Email Physician More Information